Table 1.
BRCA1 mutation carriers | BRCA2 mutation carriers | |||||
---|---|---|---|---|---|---|
Yes, n (%) | No, n (%) | Unknown status | Yes, n (%) | No, n (%) | Unknown status | |
Predictive markers | ||||||
ER-positive | 819 (24) | 2,639 (76) | 4,339 | 1,490 (77) | 434 (23) | 2,406 |
PR-positive | 662 (21) | 2,485 (79) | 4,650 | 1,099 (65) | 591 (35) | 2,640 |
HER2-positive | 182 (9) | 1,816 (91) | 5799 | 121 (13) | 847 (87) | 3,362 |
Non-TN | 580 (31) | 1,310 (69) | 5907 | 760 (85) | 136 (15) | 3,434 |
Morphology | 3,789 | 2,087 | ||||
Ductal | 3,159 (82) | 1,770 (79) | ||||
Lobular | 89 (2) | 188 (8) | ||||
Medullary | 290 (6) | 39 (2) | ||||
Other | 470 (10) | 246 (11) | ||||
Grade | 4,645 | 3,840 | ||||
Grade 1 | 81 (3) | 113 (7) | ||||
Grade 2 | 574 (18) | 700 (42) | ||||
Grade 3 | 2,497 (79) | 839 (51) | ||||
Nodal involvement | 1,103 (33) | 2,274 (67) | 4,420 | 804 (43) | 1,068 (57) | 2,458 |
Stage | 5,991 | 3,382 | ||||
Stage 0b | 65 (4) | 121 (13) | ||||
Stage 1 | 825 (46) | 327 (35) | ||||
Stage 2 | 772 (43) | 390 (41) | ||||
Stage 3 | 127 (7) | 96 (10) | ||||
Stage 4 | 17 (1) | 14 (1) |
aER, Estrogen receptor positive; HER2, Human epidermal growth factor receptor 2; PR, Progesterone receptor; TN, Triple-negative. bCarcinoma in situ.